Chardan Capital Keeps Their Buy Rating on RegenXBio (RGNX)


In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on RegenXBio (NASDAQ: RGNX), with a price target of $127.50. The company’s shares opened today at $66.90.

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 26.1% and a 55.4% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Applied Genetic Technologies.

RegenXBio has an analyst consensus of Strong Buy, with a price target consensus of $91.63.

See today’s analyst top recommended stocks >>

The company has a one-year high of $85.10 and a one-year low of $21.10. Currently, RegenXBio has an average volume of 694.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts